Managing non-paraneoplastic Lambert-Eaton myasthenic syndrome: Clinical characteristics in 25 German patients

Journal of Neuroimmunology

Volumn 217, Issue 1-2, 2009, Pages 90-94

  Pellkofer, Hannah L ^a   Armbruster, Lena ^a   Linke, Rainer ^a   Schumm, Friedrich ^c   Voltz, Raymond ^a,b  

^a UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

^c Clinic for Neurology and Neurophysiology Christophsbad   (Germany)

Author keywords

FDG PET; LEMS; Non paraneoplastic

Indexed keywords

3,4 DIAMINOPYRIDINE; ANTINUCLEAR ANTIBODY; AUTOANTIBODY; AZATHIOPRINE; CHOLINERGIC RECEPTOR ANTIBODY; CYCLOSPORIN; DOUBLE STRANDED DNA ANTIBODY; FLUORODEOXYGLUCOSE; HU ANTIBODY; IMMUNOGLOBULIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PHOSPHOLIPID ANTIBODY; PYRIDOSTIGMINE; RITUXIMAB; STEROID; THYROID ANTIBODY;

ADOLESCENT; ADULT; AGED; ANTIBODY DETECTION; ANTIBODY TITER; ARTICLE; BLOOD ANALYSIS; CHILD; CLINICAL ARTICLE; CLINICAL FEATURE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DISEASE DURATION; DISEASE MARKER; EATON LAMBERT SYNDROME; ESOPHAGUS CARCINOMA; FEMALE; GERMANY; HUMAN; IMMUNOADSORPTION; MALE; MEDICAL RECORD REVIEW; MUSCLE ACTION POTENTIAL; MUSCLE WEAKNESS; PLASMAPHERESIS; PRIORITY JOURNAL; SCHOOL CHILD; TENDON REFLEX; UTERINE CERVIX CARCINOMA; XEROSTOMIA;

ADOLESCENT; ADULT; AGED; CHILD; DIAGNOSIS, DIFFERENTIAL; FEMALE; FLUORODEOXYGLUCOSE F18; GERMANY; HUMANS; LAMBERT-EATON MYASTHENIC SYNDROME; MALE; MIDDLE AGED; PHOSPHOPYRUVATE HYDRATASE; POSITRON-EMISSION TOMOGRAPHY; YOUNG ADULT;

EID: 70449678589     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2009.09.017     Document Type: Article

References (39)

1. Antoine J.C., Cinotti L., Tilikete C., et al. [18F]Fluorodeoxyglucose positron emission tomography in the diagnosis of cancer in patients with paraneoplastic neurological syndrome and anti-Hu antibodies. Ann. Neurol. 48 (2000) 105-108
2. Bonomo L., Ciccotosto C., Guidotti A., and Storto M.L. Lung cancer staging: the role of computed tomography and magnetic resonance imaging. Eur. J. Radiol. 23 1 (1996) 35-45 Aug. Review
3. Fischer B.M., Mortensen J., Langer S.W., Loft A., Berthelsen A.K., Petersen B.I., Daugaard G., Lassen U., and Hansen H.H. A prospective study of PET/CT in initial staging of small-cell lung cancer: comparison with CT, bone scintigraphy and bone marrow analysis. Ann. Oncol. 18 2 (2007) 338-345 Feb
4. Graus F., Delattre J.Y., Antoine J.C., Dalmau J., Giometto B., Grisold W., Honnorat J., Smitt P.S., Vedeler Ch., Verschuuren J.J., Vincent A., and Voltz R. Recommended diagnostic criteria for paraneoplastic neurological syndromes. J. Neurol. Neurosurg. Psychiatry 75 8 (2004) 1135-1140 Aug
5. Graus F., Vincent A., Pozo-Rosich P., et al. Anti-glial nuclear antibody: marker of lung cancer-related paraneoplastic neurological syndromes. J. Neuroimmunol. 165 1-2 (2005) 166-171 Aug
6. Hoffmann L.A., Jarius S., Pellkofer H.L., Schüller M., Krumbholz M., König F., Johannis W., La Fougere C., Newman T., Vincent A., and Voltz R. Anti-Ma and anti-Ta associated paraneoplastic neurological syndromes: twenty-two newly diagnosed patients and review of previous cases. J. Neurol. Neurosurg. Psychiatry (2008) Jan 25
7. Lambert E.H. Defects of neuromuscular transmission in syndromes other than myasthenia gravis. Ann. N.Y. Acad. Sci. 135 1 (1966) 367-384 Jan 26
8. Lambert E.H., and Elmqvist D. Quantal components of end-plate potentials in the myasthenic syndrome. Ann. N.Y. Acad. Sci. 183 (1971) 183-199
9. Lambert E.H., and Lennon V.A. Selected IgG rapidly induces Lambert-Eaton myasthenic syndrome in mice: complement independence and EMG abnormalities. Muscle Nerve 11 11 (1988) 1133-1145 Nov
10. Lennon V.A., Kryzer T.J., Griesmann G.E., et al. Calcium-channel antibodies in the Lambert-Eaton syndrome and other paraneoplastic syndromes. N. Engl. J. Med. 332 (1995) 1467-1474
11. Leys K., Lang B., Johnston I., and Newsom-Davis J. Calcium channel autoantibodies in the Lambert-Eaton myasthenic syndrome. Ann. Neurol. 29 (1991) 307-314
12. Linke R., Schroeder M., Helmberger T., and Voltz R. Antibody-positive paraneoplastic neurologic syndromes: value of CT and PET for tumor diagnosis. Neurology 63 2 (2004) 282-286 Jul 27
13. Llinás R., Sugimori M., Lin J.W., and Cherksey B. Blocking and isolation of a calcium channel from neurons in mammals and cephalopods utilizing a toxin fraction (FTX) from funnel-web spider poison. Proc. Natl. Acad. Sci. U.S.A. 86 5 (1989) 1689-1693 Mar
14. Maddison P., Lang B., Mills K., and Newsom-Davis J. Long term outcome in Lambert-Eaton myasthenic syndrome without lung cancer. J. Neurol. Neurosurg. Psychiatry 70 2 (2001) 212-217 Feb
15. Molina R., Auge J.M., Filella X., Viñolas N., Alicarte J., Domingo J.M., and Ballesta A.M. Pro-gastrin-releasing peptide (proGRP) in patients with benign and malignant diseases: comparison with CEA, SCC, CYFRA 21-1 and NSE in patients with lung cancer. Anticancer Res. 25 3A (2005) 1773-1778 May-Jun
16. Motomura M., Lang B., Johnston I., Palace J., Vincent A., and Newsom-Davis J. Incidence of serum anti-P/O-type and anti-N-type calcium channel autoantibodies in the Lambert-Eaton myasthenic syndrome. J. Neurol. Sci. 147 1 (1997) 35-42 Mar 20
17. Oh S.J., Kurokawa K., Claussen G.C., and Ryan Jr. H.F. Electrophysiological diagnostic criteria of Lambert-Eaton myasthenic syndrome. Muscle Nerve 32 4 (2005) 515-520 Oct
18. O'Neill J.H., Murray N.M., and Newsom-Davis J. The Lambert-Eaton myasthenic syndrome. A review of 50 cases. Brain 111 Pt 3 (1988) 577-596 Jun
19. Parsons K.T., Kwok W.W., Gaur L.K., and Nepom G.T. Increased frequency of HLA class II alleles DRB1*0301 and DQB1*0201 in Lambert-Eaton myasthenic syndrome without associated cancer. Hum. Immunol. 61 8 (2000) 828-833 Aug
20. Pastorino U., Bellomi M., Landoni C., De Fiori E., Arnaldi P., Picchio M., Pelosi G., Boyle P., and Fazio F. Early lung-cancer detection with spiral CT and positron emission tomography in heavy smokers: 2-year results. Lancet 362 9384 (2003) 593-597 Aug 23
21. Pellkofer H.L., Armbruster L., Krumbholz M., Titulaer M.J., Verschuuren J.J., Schumm F., and Voltz R. Lambert-Eaton myasthenic syndrome differential reactivity of tumor versus non-tumor patients to subunits of the voltage-gated calcium channel. J. Neuroimmunol. (2008) 204 (1-2), 136-139 Nov 15
22. Pellkofer H.L., Voltz R., and Kuempfel T. Favorable response to rituximab in a patient with anti-VGCC-positive Lambert-Eaton myasthenic syndrome and cerebellar dysfunction. Muscle Nerve 40 2 (2009) 305-308 Aug
23. Pfannenberg A.C., Aschoff P., Brechtel K., et al. Low dose non-enhanced CT versus standard dose contrast-enhanced CT in combined PET/CT protocols for staging and therapy planning in non-small cell lung cancer. Eur. J. Nucl. Med. Mol. Imaging 34 (2007) 36-44
24. Ramos-Yeo Y.L., and Reyes C.V. Myasthenic syndrome (Eaton-Lambert syndrome) associated with pulmonary adenocarcinoma. J. Surg. Oncol. 34 4 (1987) 239-242 Apr
25. Rees J.H., Hain S.F., Johnson M.R., et al. The role of [18F]fluoro-2-deoxyglucose-FDG-PET scanning in the diagnosis of paraneoplastic neurological disorders. Brain (2001)
26. Sabater L., Titulaer M., Saiz A., Verschuuren J., Güre A.O., and Graus F. SOX1 antibodies are markers of paraneoplastic Lambert-Eaton myasthenic syndrome. Neurology 70 12 (2008) 924-928 Eletronic publication 2007 Nov 21
27. Sanders D.B. Lambert-Eaton myasthenic syndrome: clinical diagnosis, immune-mediated mechanisms, and update on therapies. Ann. Neurol. 37 Suppl 1 (1995) S63-S73 May Review
28. Schmahmann J.D., and Sherman J.C. The cerebellar cognitive affective syndrome. Brain 121 Pt 4 (1998) 561-579 Apr
29. Schneider J., Philipp M., Velcovsky H.G., Morr H., and Katz N. Pro-gastrin-releasing peptide (ProGRP), neuron specific enolase (NSE), carcinoembryonic antigen (CEA) and cytokeratin 19-fragments (CYFRA 21-1) in patients with lung cancer in comparison to other lung diseases. Anticancer Res. 23 2A (2003) 885-893 Mar-Apr
30. Stieber P., Dienemann H., Schalhorn A., Schmitt U.M., Reinmiedl J., Hofmann K., and Yamaguchi K. Pro-gastrin-releasing peptide (ProGRP)--a useful marker in small cell lung carcinomas. Anticancer Res. 19 4A (1999) 2673-2678 Jul-Aug
31. Takahashi T., and Momiyama A. Different types of calcium channels mediate central synaptic transmission. Nature 366 6451 (1993) 156-158 Nov 11
32. Tim R.W., Massey J.M., and Sanders D.B. Lambert-Eaton myasthenic syndrome: electrodiagnostic findings and response to treatment. Neurology 54 11 (2000) 2176-2178 Jun 13
33. Titulaer M.J., Wirtz P.W., Kuks J.B., Schelhaas H.J., van der Kooi A.J., Faber C.G., van der Pol W.L., de Visser M., Sillevis Smitt P.A., and Verschuuren J.J. The Lambert-Eaton myasthenic syndrome 1988-2008: a clinical picture in 97 patients. J. Neuroimmunol. (2008) 201-202, 153-158 Electronic publication ahead of print 2008 Jul 21
34. Titulaer M.J., Wirtz P.W., Willems L.N., van Kralingen K.W., Smitt P.A., and Verschuuren J.J. Screening for small-cell lung cancer: a follow-up study of patients with Lambert-Eaton myasthenic syndrome. J. Clin. Oncol. 26 26 (2008) 4276-4281 Sep 10
35. Urbano F.J., Pagani M.R., and Uchitel O.D. Calcium channels, neuromuscular synaptic transmission and neurological diseases. J. Neuroimmunol. 201-202 (2008) 136-144 Sep 15
36. Vincent A., Lang B., and Newsom-Davis J. Autoimmunity to the voltage-gated calcium channels underlies the Lambert-Eaton myasthenic syndrome, a paraneoplastic disorder. Trends Neurosci. 12 (1989) 496-502
37. Wirtz P.W., van Dijk J.G., van Doorn P.A., van Engelen B.M.G., van der Kooi A.J., Kuks J.B., et al. The epidemiology of the Lambert Eaton myasthenic syndrome in the Netherlands. Neurology 63 (2004) 397-398
38. Wirtz P.W., Willcox N., van der Slik A.R., et al. HLA and smoking in prediction and prognosis of small cell lung cancer in autoimmune Lambert-Eaton myasthenic syndrome. J. Neuroimmunol. 159 1-2 (2005) 230-237 Feb
39. Wirtz P.W., Wintzen A.R., and Verschuuren J.J. Lambert-Eaton myasthenic syndrome has a more progressive course in patients with lung cancer. Muscle Nerve 32 (2005) 226-229 August